Partnering
Cellmid is actively seeking partners to further develop its midkine therapeutics and diagnostics programs including its anti-midkine antibodies and oligonucleotides.
The table below provides a brief outline on the specific partnering opportunities available. For additional information please click on your areas of interest in the table below or contact us on info@cellmid.com.au.
|
Therapeutic opportunities
|
| Agents |
Disease Indication |
Partner |
Anti-midkine antibodies
|
Rheumatoid arthritis
|
Co-development partner or licensee with antibody experience and/or focus on autoimmune diseases |
| Mulitple sclerosis |
| Restenosis |
Co-development partner or licensee with antibody experience and/or focus on restenosis |
| Metastatic cancer |
Co-development partner or licensee with antibody experience and/or focus on metastatic cancers |
| Midkine protein |
AMI (Acute Myocardial Infarct) |
Co-development partner or licensee with cariovascular product development experience |
| Brain ischemia |
Co-development partner or licensee with clinical experience in acute treatment of stroke |
| Anti-midkine nucleotides |
Lung cancer |
Co-development partner with antisense or siRNA experience and/or focus an oncology and/or chemotherapy resistance |
| Colorectal cancer |
| Chemotherapy resistant cancer |